Published: Dr. Jeffrey Cummings

Dr. Jeffrey Cummings (Brain Health) co-authored “Anti-Tau Trials for Alzheimer’s Disease: A Report from the EU/US/CTAD Task Force,” which explored incorporating tau biomarkers in clinical trials to provide additional knowledge about the potential for treating Alzheimer’s Disease by targeting tau. This represents a new direction in Alzheimer’s Disease therapeutic research. The article appeared in the April issue of the Journal of Prevention of Alzheimer’s Disease.

Cummings also co-authored “Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease,” which concluded the new drug did not improve clinical ratings of dementia among patients with prodromal Alzheimer’s disease, and that cognition and daily function were worse among some patients who received verubecestat compared to those who received the placebo. The trial’s results are making scientists rethink verubecestat as viable in Alzheimer’s Disease treatment. The article appeared in the April issue of The New England Journal of Medicine.

People in the News

Patricia Butler with her chin resting on her hand.
People | July 16, 2019
One of the professors in her department describes administrative assistant Patricia Butler as "the sunshine."
Nakia Jackson-Hale holding hands with her three kids and jumping in the air outside.
People | July 15, 2019
The executive director of alumni relations & special events handles a variety of tasks for the Boyd School of Law.
Bradley Boe ready to play wheelchair rugby
People | July 11, 2019
Bradley Boe finds empowerment in a new scholarship for students with spinal cord injuries.